Oxford BioMedica plc (OXB) Given “Hold” Rating at N+1 Singer
N+1 Singer reiterated their hold rating on shares of Oxford BioMedica plc (LON:OXB) in a research report sent to investors on Tuesday morning. N+1 Singer currently has a GBX 3.30 ($0.04) price target on the biopharmaceutical company’s stock.
Separately, Jefferies Group assumed coverage on Oxford BioMedica plc in a research report on Friday, October 21st. They issued a buy rating and a GBX 8 ($0.10) target price for the company.
Oxford BioMedica plc (LON:OXB) opened at 3.515 on Tuesday. Oxford BioMedica plc has a 52 week low of GBX 2.98 and a 52 week high of GBX 8.45. The stock’s market capitalization is GBX 93.67 million. The firm has a 50 day moving average price of GBX 3.46 and a 200 day moving average price of GBX 4.15.
In other Oxford BioMedica plc news, insider Lorenzo Tallarigo purchased 79,988 shares of Oxford BioMedica plc stock in a transaction that occurred on Monday, September 26th. The stock was purchased at an average price of GBX 3 ($0.04) per share, with a total value of £2,399.64 ($2,976.85).
About Oxford BioMedica plc
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.
Receive News & Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related companies with MarketBeat.com's FREE daily email newsletter.